Novo Nordisk Flags 5–13% Sales, Profit Decline as GLP‑1 Pricing, Competition Bite

Company flags near‑term pressure in GLP‑1 market

Copenhagen‑based Novo Nordisk issues an early full‑year outlook that signals structural pressure on its GLP‑1 franchise, saying sales and operating profit could decline 5% to 13% at constant exchange rates this year. Management cites sharply lower U.S. pricing for its leading weight‑loss drug Wegovy, rising competition from rival products and the end of exclusivity in several markets as drivers of the near‑term setback. The guidance marks a pivot from the rapid growth era for semaglutide‑based therapies and forces a reassessment of commercial dynamics in obesity and diabetes care.

Novo Nordisk Faces Structural Pricing Shift

Novo Nordisk is confronting a multi‑front battle that reshapes how it approaches pricing, access and product launches. In the U.S., competitive pressure from Eli Lilly’s new entrant and from inexpensive semaglutide copies produced by compounding pharmacies compresses realised prices and reduces margins on previously high‑growth therapies. The company also notes recent loss of exclusivity for Wegovy and Ozempic in markets including China, Brazil and Canada, increasing the risk of parallel imports and lower‑priced alternatives outside its core territories.

The company is balancing short‑term affordability with long‑term demand by emphasising wider access to GLP‑1 medicines even as revenue per patient falls. Management highlights the stronger‑than‑expected launch of a Wegovy pill in the U.S., which achieves early uptake among patients, but says the incremental volume does not offset the immediate price hit to legacy injectable business. Executives portray this period as a deliberate trade‑off to extend treatment reach to “millions of patients,” while insisting on continued investment in R&D and manufacturing capacity to sustain the product pipeline.

Wider industry implications and competition

The outlook underlines an industry transition as GLP‑1 therapies move from niche, high‑priced specialty products toward broader primary‑care use and greater payer scrutiny. Competitors’ launches and compounding‑driven copycats accelerate the shift from exclusivity‑based pricing models to volume‑and‑affordability strategies, prompting manufacturers to rethink global launch sequencing, pricing agreements and patient support programmes.

Sports partnership amplifies public‑health mission

Outside commercial manoeuvres, Novo Nordisk continues brand and advocacy work through Team Novo Nordisk, which gains a wildcard entry to Milan‑Sanremo. The team’s participation reinforces the company’s public‑health messaging that diabetes need not limit achievement, linking elite sport exposure to diabetes awareness and patient education as Novo adapts its role from blockbuster seller to broader population health steward.